IGF-1 Treatment for Individuals With Short Stature Due to PAPP-A2 Deficiency

Cincinnati Children's Hospital Medical Center

Status and phase: Completed; Phase 2; Phase 1

Conditions: Short Stature

Treatments: Drug: Increlex

Study type: Interventional

Funder types: Other

Identifiers

NCT02636270

2015-6218

Details and patient eligibility

About

With this study we want to investigate the pharmacokinetic (PK) effect of a single injection of rhIGF-1 in patients with PAPP-A2 mutations compared to heterozygous carriers and healthy controls. This will be followed by treatment of PAPP-A2 deficient patients with IGF-1 for a period of one-year to assess growth velocity. Additionally, we want to further describe the phenotypic characteristics of patients with PAPP-A2 deficiency.

Full description

The 24-hour pharmacokinetic response of free and total IGF-1 and IGF binding protein-3 (IGFBP-3) to a single dose of rhIGF-1 (120 mcg/kg) in three patients with PAPP-A2 mutation compared to up to four unaffected heterozygous relatives and 2 healthy adult controls.

One-year trial of rhIGF-1 at standard dose given to the two youngest males with PAPP-A2 mutation. The primary end point of this trial will be first year height velocity. Secondary outcomes will include height standard deviation score (SDS), height velocity, and whole body and lumbar spine bone mineral density assessment. The study was amended to extend the treatment period to continue until the subject has stopped growing (or elects to withdraw). All study procedures remain the same. Important note: the treatment phase continues to follow the youngest affected male. The older affected male developed an adverse event that resulted in discontinuation of treatment.

A post-treatment follow up visit (either in-person or remote) will be completed for the study participant who remained on Increlex approximately one-year after their discontinuation of therapy.

Description of additional phenotypic characteristics of patients with PAPP-A2 mutation will be studied by collecting information on glucose and insulin metabolism, body composition, bone geometry and bone density before and after treatment with rhIGF-1. These measures will be collected at the 12-month time period, and every year thereafter until the completion of the study. All three affected siblings will take part in the phenotyping activities.

Enrollment: 7 patients

Sex: All

Ages: 10+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion and exclusion criteria

PAPP-A2 deficient

Inclusion Criteria:

• Defect in PAPP-A2 (heterozygous or homozygous mutation)

Exclusion Criteria:

• None

Healthy Volunteers

Inclusion Criteria:

• Between the ages of 18 and 30
• In general good health

Exclusion Criteria:

• Any medications (with the exception of contraceptives)
• Pregnancy

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

7 participants in 1 patient group

PAPP-A2 deficient patients

Experimental group

Description:

Patients deficient in PAPP-A2 with short stature will be treated with Increlex (rhIGF-1)

Treatment:

Drug: Increlex